

## OPPI Coverage Dossier May 2025



## **INDEX**


S.no	Date	Publication	Edition	Link
Online				
1	17 May	ET pharma	Online	Natura Non Facit Saltum: Incremental Innovation in Pharmaceuticals
2	5 May	Scrip	Online	OPPI's Matai On Section 3(d) Of India's Patent Regulations: Now's The Time To Open Up



## **ONLINE**



Publication	ET pharma
Date	17 May
Edition	Online
Headline	Natura Non Facit Saltum: Incremental Innovation in Pharmaceuticals





Publication	Scrip
Date	5 May
Edition	Online
Headline	OPPI's Matai On Section 3(d) Of India's Patent Regulations: Now's The Time To Open Up

## OPPI's Matai On Section 3(d) Of India's Patent Regulations: Now's The Time To Open Up

Industry Group's Head Shares Views In Audio Interview

05 May 2025 • By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India's patent regulations and innovator firms' experience of the Bolar provision. There's also a "compelling reason" to consider regulatory data protection, he claims.



(OPPI)

"The needle has moved," declares Anil Matai, director general of the Organization of Pharmaceutical Producers of India (OPPI), describing India's evolving intellectual property rights regime, which saw the